NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

CompletedPhase 1

Sponsor: Pfizer

Conditions: Healthy Participants

Interventions: Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran

Countries: United States

This is a drug-drug interaction study to assess the effects of PF-07321332/ritonavir and ritonavir on the Pharmacokinetic (PK) of dabigatran in healthy volunteers. PK will be evaluated for PF-07321332 and ritonavir. Dabigatran is being utilized as a P-gp substrate

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Body Mass Index (BMI) of 17.5 to 30.5 kg.m2; and a total body weight \>50 kg (110 lbs)
* Female participants must have a negative pregnancy test

Exclusion Criteria:

* Positive test for SARS-Co-V2 at the time of screening or Day -1
* Active pathological bleeding or risk of bleeding
* Positive urine drug test
* History of sensitivity to heparin or heparin induced thrombocytopenia
* Participants who have been vaccinated for COVID-19 in the past 7 days

Locations (1)

Hollywood, Florida, United States